NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...
Medical Device Network on MSN
Hims & Hers Health signs agreement to acquire YourBio Health
The transaction closure is anticipated in early 2026, contingent on regulatory approvals and other customary conditions.
Hims & Hers Health (HIMS) has entered into an agreement to acquire YourBio Health, a Boston-based maker of capillary whole ...
Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, ...
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...
Hims & Hers is fundamentally undervalued, trading at a forecast P/S ratio of 3.5 despite strong 88% YoY growth and European expansion. Low valuation and scaling by ZAVA lead to a buy rating. Short ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback